Price$0.27-0.00 (-0.04%)
02:00 PM07:45 PM
News · 26 weeks83+33%
2026-03-012026-08-23
Mix2890d
- Insider13(46%)
- Other9(32%)
- SEC Filings4(14%)
- Leadership1(4%)
- Market1(4%)
Latest news
25 items- SECSEC Form 424B3 filed by Medicus Pharma Ltd.424B3 - Medicus Pharma Ltd. (0001997296) (Filer)
- NEWSMedicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateCompany Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teverelix® Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Expansion PHILADELPHIA, PA / ACCESS Newswire / August 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today reported financial results for the three and six months ended June 30, 2026, and provided a corporate update highlighting significant regulatory, clinical and strategic achievements across its development portfolio.During th
- SECSEC Form 10-Q filed by Medicus Pharma Ltd.10-Q - Medicus Pharma Ltd. (0001997296) (Filer)
- PRMedicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United KingdomPHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced the appointment of Faisal Mehmud, MD, MRCP, as Chief Executive Officer of Antev Limited, United Kingdom ("Antev"), the Company’s United Kingdom subsidiary, effective August 30, 2026. Dr. Mehmud will continue to serve as Chief Medical Officer of Medicus and Co-Chairman of Antev providing unified scientific, clinical, regulatory and operational leadership as the Company advances the global development of Teverelix® across mu
- PRMedicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with EndometriosisPHILADELPHIA, July 31, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that the United Arab Emirates (UAE) Department of Health – Abu Dhabi ("DOH") has granted Investigational New Drug ("IND") authorization for the Company's PRECISION-E2 Phase 2a clinical study evaluating Teverelix® in women with moderate-to-severe symptomatic endometriosis, a chronic estrogen-dependent inflammatory disease that affects approximately one in ten women of reproductive age worldwide. The authorization follows co
- PRMedicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin SyndromePHILADELPHIA, July 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that the U.S. Food and Drug Administration ("FDA") has completed its safety review of the Company's Investigational New Drug ("IND") application for SKNJCT-005 and issued a "Study May Proceed" letter authorizing the initiation of the Company's NDA-enabling registrational Phase 2b clinical study evaluating SkinJect® (D-MNA) 200 mcg in patients with Gorlin Syndrome presenting with multiple basal cell carcinomas ("BCCs"). The
- PRMedicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary RetentionPHILADELPHIA, July 16, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that it has received written feedback from the U.S. Food and Drug Administration ("FDA") and central Institutional Review Board ("IRB") approval, with modifications, for its optimized Phase 2 clinical study of Teverelix® in men following a first episode of acute urinary retention ("AUR"). The randomized, double-blind, placebo-controlled, multicenter study, designated ANT-2111-02, is a novel study designed to evaluate the p
- PRMedicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026PHILADELPHIA, June 22, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that it will participate in the 2026 Bio International Conference, being held on June 22-25, 2026, in San Diego, California. Dr. Faisal Mehmud, Chief Medical Officer of Medicus, will deliver a company presentation highlighting recent clinical, regulatory and strategic advancements across the Company’s development portfolio. The presentation will provide updates on SkinJect®, an investigational Doxorubicin containing disso
- PRMedicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin SyndromePHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced the submission of a Rare Pediatric Disease Designation ("RPDD") request to the U.S. Food and Drug Administration ("FDA") for SkinJect®, the Company's investigational doxorubicin-containing microneedle array patch (D-MNA), for the treatment of basal cell carcinoma ("BCC") in patients with Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome. The RPDD submission was made pursuant to Section 529 of the Federa
- PRMedicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome ProgramPHILADELPHIA, June 11, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced submission of an Investigational New Drug (IND) application to the Department of Health, Abu Dhabi (DOH) for PRECISION-E2, a first-of-its-kind, Phase 2a genomics-enabled clinical trial evaluating Teverelix® in women with symptomatic endometriosis in the United Arab Emirates (UAE). The PRECISION-E2 study is designed to combine clinical outcomes, hormonal biomarkers, pharmacokinetic and pharmacodynamic measurements, and geno
- PRMedicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European SubmissionPHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced the successful submission of a substantial modification application through the European Union Clinical Trials Information System (CTIS) supporting the planned Phase 2b study of Teverelix® in advanced prostate cancer (APC). The submission represents an important milestone in Medicus' strategy to advance Teverelix® toward registrational development focused on one of the largest unmet needs in prostate cancer treatment: pat
- SECSEC Form 424B3 filed by Medicus Pharma Ltd.424B3 - Medicus Pharma Ltd. (0001997296) (Filer)
- SECMedicus Pharma Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Medicus Pharma Ltd. (0001997296) (Filer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Smith Andrew Alasdair4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Director Rodgers Cathy Mcmorris4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Director Raju Ajay4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Mehmud Faisal4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Director May Sara R.4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Director Mahaffy Patrick J4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Director Kaiser Larry4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Director Fishman Barry4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Brennan Edward J.4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Director Ciaruffoli Robert J.4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by President and CFO Bonner Carolyn F.4 - Medicus Pharma Ltd. (0001997296) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Bokhari Raza4 - Medicus Pharma Ltd. (0001997296) (Issuer)
MDCX FAQ
4 questionsWhere does MDCX stock trade?
Medicus Pharma Ltd. (MDCX) is listed on NASDAQ.What sector and industry is MDCX in?
Medicus Pharma Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to MDCX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MDCX side-by-side with any of them on Quantisnow.How can I track MDCX on Quantisnow?
Quantisnow aggregates Medicus Pharma Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MDCX to receive live email and push alerts on every new disclosure.